An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation

Abhinav P. Acharya, Kathryn M. Theisen, Andres Correa, Thiagarajan Meyyappan, Abraham Apfel, Tao Sun, Tatum V. Tarin, Steven R. Little

Research output: Contribution to journalArticle

Abstract

Although hematuria (blood in urine) is the most common symptom of bladder cancer, 70–98% of hematuria cases are benign. These hematuria patients unnecessarily undergo costly, invasive, and expensive evaluation for bladder cancer. Therefore, there remains a need for noninvasive office-based tests that can rapidly and reliably rule out bladder cancer in patients undergoing hematuria evaluation. Herein, a clinical assay for matrix metalloproteinases (“Ammps”) is presented, which generates a visual signal based on the collagenase activity (in urine of patients) on the Ammps substrates. Ammps substrates are generated by crosslinking gelatin with Fe(II) chelated alginate nanoparticles, which precipitate in urine samples. The cleavage of gelatin-conjugated alginate (Fe(II)) nanoparticles by collagenases generates free-floating alginate (Fe(II)) nanoparticles that participate in Fenton's reaction to generate a visual signal. In a pilot study of 88 patients, Ammps had 100% sensitivity, 85% specificity, and a negative predictive value (NPV) of 100% for diagnosing bladder cancer. This high NPV can be useful in ruling out bladder cancer in patients referred for hematuria evaluation.

Original languageEnglish (US)
Article number1700808
JournalAdvanced Healthcare Materials
Volume6
Issue number22
DOIs
StatePublished - Nov 22 2017
Externally publishedYes

Fingerprint

Point-of-Care Systems
Hematuria
Matrix Metalloproteinases
Urinary Bladder Neoplasms
Assays
Alginate
Urine
Nanoparticles
Collagenases
Gelatin
Substrates
Crosslinking
Precipitates
Blood
Metalloproteases
Sensitivity and Specificity
alginic acid

Keywords

  • bladder cancer
  • cost-effective
  • diagnostics
  • MMPs
  • urine test

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Pharmaceutical Science

Cite this

An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation. / Acharya, Abhinav P.; Theisen, Kathryn M.; Correa, Andres; Meyyappan, Thiagarajan; Apfel, Abraham; Sun, Tao; Tarin, Tatum V.; Little, Steven R.

In: Advanced Healthcare Materials, Vol. 6, No. 22, 1700808, 22.11.2017.

Research output: Contribution to journalArticle

Acharya, Abhinav P. ; Theisen, Kathryn M. ; Correa, Andres ; Meyyappan, Thiagarajan ; Apfel, Abraham ; Sun, Tao ; Tarin, Tatum V. ; Little, Steven R. / An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation. In: Advanced Healthcare Materials. 2017 ; Vol. 6, No. 22.
@article{41b5a16fa3e34ee2a9704b04df7c796f,
title = "An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation",
abstract = "Although hematuria (blood in urine) is the most common symptom of bladder cancer, 70–98{\%} of hematuria cases are benign. These hematuria patients unnecessarily undergo costly, invasive, and expensive evaluation for bladder cancer. Therefore, there remains a need for noninvasive office-based tests that can rapidly and reliably rule out bladder cancer in patients undergoing hematuria evaluation. Herein, a clinical assay for matrix metalloproteinases (“Ammps”) is presented, which generates a visual signal based on the collagenase activity (in urine of patients) on the Ammps substrates. Ammps substrates are generated by crosslinking gelatin with Fe(II) chelated alginate nanoparticles, which precipitate in urine samples. The cleavage of gelatin-conjugated alginate (Fe(II)) nanoparticles by collagenases generates free-floating alginate (Fe(II)) nanoparticles that participate in Fenton's reaction to generate a visual signal. In a pilot study of 88 patients, Ammps had 100{\%} sensitivity, 85{\%} specificity, and a negative predictive value (NPV) of 100{\%} for diagnosing bladder cancer. This high NPV can be useful in ruling out bladder cancer in patients referred for hematuria evaluation.",
keywords = "bladder cancer, cost-effective, diagnostics, MMPs, urine test",
author = "Acharya, {Abhinav P.} and Theisen, {Kathryn M.} and Andres Correa and Thiagarajan Meyyappan and Abraham Apfel and Tao Sun and Tarin, {Tatum V.} and Little, {Steven R.}",
year = "2017",
month = "11",
day = "22",
doi = "10.1002/adhm.201700808",
language = "English (US)",
volume = "6",
journal = "Advanced healthcare materials",
issn = "2192-2640",
publisher = "John Wiley and Sons Ltd",
number = "22",

}

TY - JOUR

T1 - An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation

AU - Acharya, Abhinav P.

AU - Theisen, Kathryn M.

AU - Correa, Andres

AU - Meyyappan, Thiagarajan

AU - Apfel, Abraham

AU - Sun, Tao

AU - Tarin, Tatum V.

AU - Little, Steven R.

PY - 2017/11/22

Y1 - 2017/11/22

N2 - Although hematuria (blood in urine) is the most common symptom of bladder cancer, 70–98% of hematuria cases are benign. These hematuria patients unnecessarily undergo costly, invasive, and expensive evaluation for bladder cancer. Therefore, there remains a need for noninvasive office-based tests that can rapidly and reliably rule out bladder cancer in patients undergoing hematuria evaluation. Herein, a clinical assay for matrix metalloproteinases (“Ammps”) is presented, which generates a visual signal based on the collagenase activity (in urine of patients) on the Ammps substrates. Ammps substrates are generated by crosslinking gelatin with Fe(II) chelated alginate nanoparticles, which precipitate in urine samples. The cleavage of gelatin-conjugated alginate (Fe(II)) nanoparticles by collagenases generates free-floating alginate (Fe(II)) nanoparticles that participate in Fenton's reaction to generate a visual signal. In a pilot study of 88 patients, Ammps had 100% sensitivity, 85% specificity, and a negative predictive value (NPV) of 100% for diagnosing bladder cancer. This high NPV can be useful in ruling out bladder cancer in patients referred for hematuria evaluation.

AB - Although hematuria (blood in urine) is the most common symptom of bladder cancer, 70–98% of hematuria cases are benign. These hematuria patients unnecessarily undergo costly, invasive, and expensive evaluation for bladder cancer. Therefore, there remains a need for noninvasive office-based tests that can rapidly and reliably rule out bladder cancer in patients undergoing hematuria evaluation. Herein, a clinical assay for matrix metalloproteinases (“Ammps”) is presented, which generates a visual signal based on the collagenase activity (in urine of patients) on the Ammps substrates. Ammps substrates are generated by crosslinking gelatin with Fe(II) chelated alginate nanoparticles, which precipitate in urine samples. The cleavage of gelatin-conjugated alginate (Fe(II)) nanoparticles by collagenases generates free-floating alginate (Fe(II)) nanoparticles that participate in Fenton's reaction to generate a visual signal. In a pilot study of 88 patients, Ammps had 100% sensitivity, 85% specificity, and a negative predictive value (NPV) of 100% for diagnosing bladder cancer. This high NPV can be useful in ruling out bladder cancer in patients referred for hematuria evaluation.

KW - bladder cancer

KW - cost-effective

KW - diagnostics

KW - MMPs

KW - urine test

UR - http://www.scopus.com/inward/record.url?scp=85029095804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029095804&partnerID=8YFLogxK

U2 - 10.1002/adhm.201700808

DO - 10.1002/adhm.201700808

M3 - Article

C2 - 28885787

AN - SCOPUS:85029095804

VL - 6

JO - Advanced healthcare materials

JF - Advanced healthcare materials

SN - 2192-2640

IS - 22

M1 - 1700808

ER -